卖什么
Creating new protein-based drugs at scale
商业模式拆解
买家：谁掌握预算？
未核实Biotech and pharma program leads who commission a manufacturing programme.
触发点：什么让他们现在购买？
AI can design drugs faster than traditional manufacturing can make them; antimicrobial resistance needs pathogen-specific phages in days.
工作流：什么输入变成什么输出？
Computational design coupled with high-throughput cell-free wet-lab validation, then scale-up from picoliter droplets to GMP volumes on one platform.
经济账：省了什么，怎么收费？
Claims over 90% gross margin at $1-2k COGS versus $5-10k traditional; grant funding (SPRIND challenge, EUR 250,000 TUM award).
渠道：怎么接触到客户？
Programme-based engagements: "Discuss a programme" contact.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2023 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.